A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Rheumatoid Arthritis Clinical Trial

Official title:

A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01408602
• Other study ID #: MRC2011-001
• Status: Active, not recruiting
• Phase: Phase 2
• First received: August 2, 2011
• Last updated: May 9, 2014
• Start date: November 2011
• Est. completion date: July 2014

Study information

• Verified date: May 2014
• Source: Molecular Research Center, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.

Description:

This is a double-blind, randomized, placebo-controlled study to assess the safety and efficacy of MRC375 at 75 mg or 150 mg with matching placebo (taken tid with meal or light snack) in patients with moderate to severe RA. Patients will be randomized to one of the following study arms for 24 weeks:

• Treatment 1, Placebo: 2 tablets taken tid

• Treatment 2, MRC375: 1 tablet of 75 mg tetracycline HCL plus 1 matching placebo tablet taken tid. Total daily dose = 225 mg.

• Treatment 3, MRC375: 2 tablets of 75 mg tetracycline HCL taken tid. Total daily dose = 450 mg.

Study medication should be taken within 30 minutes of a meal or light snack (either before or after).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Is 18 years of age

2. Is diagnosed with moderate to severe adult onset RA > = 6 months duration, as defined by the 1987 ACR classification criteria

3. Has moderate to severe RA as defined by:

• =4 tender joints/painful (28 joint count) at screening

• =4 swollen joints (28 joint count) at screening

4. Has a Health Assessment Questionnaire (HAQ) of >0

5. Has a physician global assessment (Likert scale) of >0

6. Has a patient global assessment of pain (Likert scale) of >0

7. Has a patient assessment of pain (Likert scale) of >0

8. Has stable doses of the following allowable medications during the study, if applicable:

• Stable dose of NSAIDs or other analgesics for at least 2 weeks prior to administration of study drug at regulatory approved doses

• Stable dose of methotrexate 7.5 mg to 25 mg/day once weekly for at least 6 weeks prior to administration of study drug (no changes in dosing regimen for 4 weeks prior to screening)

• Stable dose of hydroxychloroquine either monotherapy or in combination with methotrexate 8 weeks prior to administration of study drug

9. Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea

10. If female of childbearing potential, must agree to use one of the following acceptable birth control methods:

• Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to screening, hysterectomy, or bilateral oophorectomy);

• Intrauterine device (IUD) in place for at least 3 months prior to first dose of study drug;

• Abstinence (not having sexual intercourse);

• Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion;

• Stable hormonal contraceptive for at least 3 months prior to study and through study completion

11. If female of childbearing potential, has a negative serum hCG pregnancy test at screening

12. Is able to swallow whole tablets of orally administered medication

13. Is able to understand and provide signed informed consent.

Exclusion Criteria:

1. Has been diagnosed with any other inflammatory arthritis (eg, psoriatic arthritis)

2. Has a secondary type of arthritis (eg, osteoarthritis) that would interfere with study evaluations

3. Has taken the following drugs within the timeframe specified below:

• Infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab) - Within 12 weeks prior to the administration of study drug;

• Rituximab - Within 12 months prior to the administration of study drug;

• Disease-modifying antirheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above including but not limited to: sulfasalazine, gold, leflunomide, penicillamine, dapsone, azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil - Within 12 weeks prior to the administration of study drug;

• Any steroids (glucocorticoids); glucocorticoids must be discontinued for at least 4 weeks prior to administration of study drug. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to administration of study drug.

• Note: Use of probiotics is allowed and is NOT an exclusion criterion.

4. Has a uncontrolled symptoms of fibromyalgia with sufficient symptoms requiring treatment (NOTE: patients on a stable dose of treatment for symptoms of fibromyalgia = 4 weeks will be allowed in the study.)

5. Has a history of allergic reaction to tetracycline or other related drugs

6. Had major surgery or trauma within 28 days prior to screening

7. Is concurrently using minocycline or doxycycline (washout of 4 weeks required before the administration of study drug)

8. Patients who are on chronic antibiotics or who are on antibiotics for GI infections (such as Clostridium difficile)

9. Has clinically significant ECG abnormalities

10. Has any clinically significant abnormal laboratory test results found during medical screening including: AST or ALT > 2 x upper limit of normal or serum creatinine > 2.0 mg/dL

11. Has clinically significant history or presence of any gastrointestinal pathology (eg, chronic diarrhea, inflammatory bowel disease, acute diverticulitis), irritable bowel syndrome, unresolved gastrointestinal symptoms (eg. diarrhea, vomiting, symptoms of acute diverticulitis), liver or kidney disease, gastric bypass, gastric stapling, use of Lap-Band®, or other conditions known to or which might interfere with the absorption, distribution, metabolism, or excretion of the drug

12. Has any historical or active neurological, endocrine, cardiovascular, pulmonary, hematological, psychiatric, or metabolic disease that is considered clinically significant by the Investigator

13. Has known history of HIV, hepatitis B or C (patients that have positive hepatitis B serology due to prior vaccination will be allowed in the study)

14. Has an active malignancy of any type or history of malignancy. Patients who have a history of a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma (ie. non melanoma skin cancer)and/or localized carcinoma in situ of the cervix are eligible. Patients with a history of other malignancies that have been treated and who have no evidence of recurrence for at least 5 years before study enrollment are also eligible.

15. Has difficulty swallowing tablets

16. Is ACR Functional Class IV (limited ability to perform usual self-care, vocational, and avocational activities)

17. Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)

18. Has clinically significant mental illness (to be determined by the Investigator)

19. Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements. Has exposure to any investigational agent within 30 days prior to study entry.

20. Was previously enrolled in this study

21. Has recent history of bacterial intestinal tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)

22. Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• MRC375
MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
• Matching Placebo
Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
• MRC375 150mg
MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks

Locations

Country	Name	City	State
United States	Providence Health Partners	Dayton	Ohio
United States	Riverside Clinical Research	Edgewater	Florida
United States	Apex Clinical Research	Kennewick	Washington
United States	Advanced BioMedical Research of America	Las Vegas	Nevada
United States	Analan Clinical Research	Lenexa	Kansas
United States	Valerius Medical Group	Long Beach	California
United States	Trial Concierge/Pacific Clinical Studies	Los Alamitos	California
United States	Axis Clinical Trials	Los Angeles	California
United States	Global Clinical Professionals	Miami	Florida
United States	Paramount Medical Research & Consulting, LLC	Middleburg Heights	Ohio
United States	Mobile Diagnostic Center Rheumatology	Mobile	Alabama
United States	South Puget Sound Clinical Research Center	Olympia	Washington
United States	Quality Clinical Research, Inc.	Omaha	Nebraska
United States	Trial Concierge	Owensboro	Kentucky
United States	The Arthritis Center	Palm Harbor	Florida
United States	Arthritis Center of Reno	Reno	Nevada
United States	PMG Research of Salisbury	Salisbury	North Carolina
United States	Lakeview Medical Research	Summerfield	Florida
United States	The Center for Excellence in Aging and Geriatric Health	Williamsburg	Virginia

Sponsors (6)

Lead Sponsor	Collaborator
Molecular Research Center, Inc.	BARC Global Central Laboratory, Bilcare Global Clinical Supplies, Camargo Pharmaceutical Services, Clin Data Services, Harrison Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy evaluated of both doses of MRC375 compared to placebo after 24 weeks of treatment as measured by the rate of achievement of 20% improvement in ACR criteria	evaluate efficacy of both doses of MRC375 compared to placebo after 24 weeks of treatment, as measured by a rate of achievement of 20% improvement in American College of Rheumatology (ACR) criteria (ACR20) at Week 24	24 weeks	No
Secondary	Safety and tolerability of both doses of MRC375	evaluate the safety and tolerability of both doses of MRC375 tablets	24 weeks	Yes
Secondary	Compare the Efficacy of two doses of MRC375 when compared to a placebo for the change from baseline screening in each of the individual ACR components measuring RA after 24 weeks of treatment	compare the efficacy of 2 doses of MRC375 tablets (75 mg tid and 150 mg tid) when compared to placebo for the change from baseline screening in each of the individual ACR components measuring rheumatoid arthritis (RA) after 24 weeks of treatment.	24 weeks	No